Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984

A. H G J Schrijvers, M. Gerretsen, M. van Walsum, B. J M Braakhuis, J. J. Quak, G. B. Snow, G. A M S van Dongen

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

In previous reports we have described the development of mAb K984, reactive with an epitope expressed on the outer cell surface of undifferentiated, proliferating cells in normal stratified squamous epithelia and their neoplastic counterparts [28, 30]. The K984 antigen was also found to be homogeneously expressed by in vitro cultured squamous cell carcinoma (SCC) cell lines. In the present study we demonstrate that mAb K984 induces a significant, dose-dependent growth inhibition when SCC cells are grown in vitro as monolayer cultures in the presence of mAb K984. These data seem to indicate that mAb K984 has potential for tumour targeting, especially in a therapeutic setting. As a first approach to evaluate the suitability of mAb K984 for tumour targeting in vivo, radiolabelled mAb K984 was administered to SCC-xenografted nude mice. Selective tumour accumulation of mAb K984 was observed. Tumour to blood ratios and tumour to non-tumour ratios, as based on the biodistribution data, were at least ten times higher in case of the specific mAb K984 when compared to another non-specific, isotypematched control antibody. mAb K984 was also capable of visualizing tumour deposits in xenografted nude mice. The corollary of these findings is that the mAb K984-defined antigen probably is involved in the regulation of proliferation of stratified squamous epithelium and squamous cell carcinoma and that mAb K984 has potential for specific tumour targeting.

Original languageEnglish
Pages (from-to)252-258
Number of pages7
JournalCancer Immunology Immunotherapy
Volume34
Issue number4
DOIs
Publication statusPublished - 1 Jul 1992

Cite this

Schrijvers, A. H G J ; Gerretsen, M. ; van Walsum, M. ; Braakhuis, B. J M ; Quak, J. J. ; Snow, G. B. ; van Dongen, G. A M S. / Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984. In: Cancer Immunology Immunotherapy. 1992 ; Vol. 34, No. 4. pp. 252-258.
@article{9c222e8b24364dee87e65e861d6f1d7f,
title = "Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984",
abstract = "In previous reports we have described the development of mAb K984, reactive with an epitope expressed on the outer cell surface of undifferentiated, proliferating cells in normal stratified squamous epithelia and their neoplastic counterparts [28, 30]. The K984 antigen was also found to be homogeneously expressed by in vitro cultured squamous cell carcinoma (SCC) cell lines. In the present study we demonstrate that mAb K984 induces a significant, dose-dependent growth inhibition when SCC cells are grown in vitro as monolayer cultures in the presence of mAb K984. These data seem to indicate that mAb K984 has potential for tumour targeting, especially in a therapeutic setting. As a first approach to evaluate the suitability of mAb K984 for tumour targeting in vivo, radiolabelled mAb K984 was administered to SCC-xenografted nude mice. Selective tumour accumulation of mAb K984 was observed. Tumour to blood ratios and tumour to non-tumour ratios, as based on the biodistribution data, were at least ten times higher in case of the specific mAb K984 when compared to another non-specific, isotypematched control antibody. mAb K984 was also capable of visualizing tumour deposits in xenografted nude mice. The corollary of these findings is that the mAb K984-defined antigen probably is involved in the regulation of proliferation of stratified squamous epithelium and squamous cell carcinoma and that mAb K984 has potential for specific tumour targeting.",
keywords = "Radioimmunoconjugate, Squamous cell carcinoma, Tumour targeting",
author = "Schrijvers, {A. H G J} and M. Gerretsen and {van Walsum}, M. and Braakhuis, {B. J M} and Quak, {J. J.} and Snow, {G. B.} and {van Dongen}, {G. A M S}",
year = "1992",
month = "7",
day = "1",
doi = "10.1007/BF01741793",
language = "English",
volume = "34",
pages = "252--258",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "4",

}

Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984. / Schrijvers, A. H G J; Gerretsen, M.; van Walsum, M.; Braakhuis, B. J M; Quak, J. J.; Snow, G. B.; van Dongen, G. A M S.

In: Cancer Immunology Immunotherapy, Vol. 34, No. 4, 01.07.1992, p. 252-258.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Potential for targeting head and neck squamous cell carcinoma with monoclonal antibody K984

AU - Schrijvers, A. H G J

AU - Gerretsen, M.

AU - van Walsum, M.

AU - Braakhuis, B. J M

AU - Quak, J. J.

AU - Snow, G. B.

AU - van Dongen, G. A M S

PY - 1992/7/1

Y1 - 1992/7/1

N2 - In previous reports we have described the development of mAb K984, reactive with an epitope expressed on the outer cell surface of undifferentiated, proliferating cells in normal stratified squamous epithelia and their neoplastic counterparts [28, 30]. The K984 antigen was also found to be homogeneously expressed by in vitro cultured squamous cell carcinoma (SCC) cell lines. In the present study we demonstrate that mAb K984 induces a significant, dose-dependent growth inhibition when SCC cells are grown in vitro as monolayer cultures in the presence of mAb K984. These data seem to indicate that mAb K984 has potential for tumour targeting, especially in a therapeutic setting. As a first approach to evaluate the suitability of mAb K984 for tumour targeting in vivo, radiolabelled mAb K984 was administered to SCC-xenografted nude mice. Selective tumour accumulation of mAb K984 was observed. Tumour to blood ratios and tumour to non-tumour ratios, as based on the biodistribution data, were at least ten times higher in case of the specific mAb K984 when compared to another non-specific, isotypematched control antibody. mAb K984 was also capable of visualizing tumour deposits in xenografted nude mice. The corollary of these findings is that the mAb K984-defined antigen probably is involved in the regulation of proliferation of stratified squamous epithelium and squamous cell carcinoma and that mAb K984 has potential for specific tumour targeting.

AB - In previous reports we have described the development of mAb K984, reactive with an epitope expressed on the outer cell surface of undifferentiated, proliferating cells in normal stratified squamous epithelia and their neoplastic counterparts [28, 30]. The K984 antigen was also found to be homogeneously expressed by in vitro cultured squamous cell carcinoma (SCC) cell lines. In the present study we demonstrate that mAb K984 induces a significant, dose-dependent growth inhibition when SCC cells are grown in vitro as monolayer cultures in the presence of mAb K984. These data seem to indicate that mAb K984 has potential for tumour targeting, especially in a therapeutic setting. As a first approach to evaluate the suitability of mAb K984 for tumour targeting in vivo, radiolabelled mAb K984 was administered to SCC-xenografted nude mice. Selective tumour accumulation of mAb K984 was observed. Tumour to blood ratios and tumour to non-tumour ratios, as based on the biodistribution data, were at least ten times higher in case of the specific mAb K984 when compared to another non-specific, isotypematched control antibody. mAb K984 was also capable of visualizing tumour deposits in xenografted nude mice. The corollary of these findings is that the mAb K984-defined antigen probably is involved in the regulation of proliferation of stratified squamous epithelium and squamous cell carcinoma and that mAb K984 has potential for specific tumour targeting.

KW - Radioimmunoconjugate

KW - Squamous cell carcinoma

KW - Tumour targeting

UR - http://www.scopus.com/inward/record.url?scp=0026540936&partnerID=8YFLogxK

U2 - 10.1007/BF01741793

DO - 10.1007/BF01741793

M3 - Article

VL - 34

SP - 252

EP - 258

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 4

ER -